Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $1.0952W HIGH $2.76
Volume
619.15 K
Value Traded
1.35 M
Short % Float
5.64%
Days to Cover
5.7
-1.54%Week
0%1 Month
+27.15%3 Month
-18.3%6 Month
-87.29%5 Year
-88.18%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
211.03 M
EPS (TTM)
-1.06
P/E Ratio
-
Ent. Value
46.00 M
Total Shares
111.59 M
Float Shares
108.93 M
Insiders
26.52%
Institutions
66.11%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
ALEC Catalyst Timeline
Dated clinical, regulatory and corporate events for Alector, Inc.
Catalyst Timeline
Dated clinical, regulatory & corporate events for Alector, Inc.
237Total events
11Upcoming
36Tier-1 (high impact)
2018 to 2029Coverage
Upcoming catalysts 2
Event history 50
▼Equity OfferingCorporate
Pricing of underwritten offering of 36,600,000 shares at $2.05/share (~$75.0M gross)
▲Partnership / LicenseAL050Corporate
Alector enters global license agreement with Genentech for AL050
Parkinson's Disease and Other Neurodegenerative Diseasessource ↗
▲Milestone PaymentAL050Corporate
Alector to receive $100 million upfront payment from Genentech
Parkinson's Disease and Other Neurodegenerative Diseasessource ↗
▼Trial DiscontinuednivisnebartDiscontinuedTrial
PROGRESS-AD Phase 2 trial of nivisnebart discontinued after interim futility analysis
early Alzheimer's diseasesource ↗
◆Interim AnalysisnivisnebartDiscontinuedTrial
Independent interim futility analysis of PROGRESS-AD Phase 2 trial
early Alzheimer's diseasesource ↗
◆Oral PresentationlatozinemabPresentation
Presentation of INFRONT-3 Phase 3 results at scientific meeting
frontotemporal dementiasource ↗
▲Development Candidate NominationAL137Preclinical
Lead candidate AL137 selected for ABC-enabled anti-amyloid beta antibody
Alzheimer's diseasesource ↗
▲Development Candidate NominationAL050Preclinical
Lead candidate AL050 selected for ABC-enabled GCase enzyme replacement therapy
Parkinson's diseasesource ↗
▼Topline ReadoutlatozinemabClinical Data
Topline results from Phase 3 INFRONT-3 trial of latozinemab in FTD-GRN
frontotemporal dementia due to GRN mutationsource ↗
▼Trial DiscontinuedlatozinemabTrial
Discontinuation of open-label extension and continuation study for latozinemab
frontotemporal dementia due to GRN mutationsource ↗
▼Topline ReadoutlatozinemabClinical Data
Topline results from INFRONT-3 Phase 3 trial of latozinemab announced
frontotemporal dementia due to GRN mutationsource ↗
▼Trial DiscontinuedlatozinemabTrial
Open-label extension and continuation study for latozinemab discontinued
frontotemporal dementia due to GRN mutationsource ↗
▲Patent GrantedlatozinemabIP / Competition
U.S. patent issued covering methods of treatment using latozinemab in FTD-GRN
FTD-GRNsource ↗
●PublicationAL101Presentation
Publication of AL101 development manuscript in Alzheimer's Research & Therapy
Alzheimer's diseasesource ↗
◆Management ChangeCorporate
Marc Grasso to depart as CFO, Neil Berkley appointed Interim CFO effective June 20, 2025
▲Enrollment CompleteAL101Trial
Complete enrollment in PROGRESS-AD Phase 2 trial of AL101/GSK4527226
early Alzheimer's diseasesource ↗
◆Oral PresentationAL002DiscontinuedPresentation
Oral presentation of INVOKE-2 Phase 2 results for AL002 at AD/PD 2025
early Alzheimer's diseasesource ↗
▲Enrollment CompleteAL101Trial
Completed enrollment in PROGRESS-AD Phase 2 trial of AL101/GSK4527226 in early Alzheimer's disease
early Alzheimer's diseasesource ↗
●Oral PresentationPresentation
Educational webinar on anti-amyloid beta and GCase programs and ABC advancements
▲Enrollment CompletenivisnebartDiscontinuedTrial
Enrollment completed for PROGRESS-AD Phase 2 trial of nivisnebart
early Alzheimer's diseasesource ↗
●IND Enabling CompletePreclinical
Advance ADP037-ABC and ADP050-ABC toward IND-enabling studies
◆Topline ReadoutlatozinemabClinical Data
Data readout from pivotal INFRONT-3 trial of latozinemab
frontotemporal dementia due to progranulin gene mutation (FTD-GRN)source ↗
▼Primary Endpoint MissedAL002DiscontinuedClinical Data
AL002 failed to meet primary endpoint CDR-SB in INVOKE-2
early Alzheimer's diseasesource ↗
▼Trial DiscontinuedAL002DiscontinuedTrial
Stopping long-term extension study of AL002
early Alzheimer's diseasesource ↗
●Enrollment UpdateAL101Trial
PROGRESS-AD enrollment reached more than one-third of target 282
early Alzheimer's diseasesource ↗
▲Debt Royalty FinancingCorporate
Alector secures up to $50 million credit facility from Hercules Capital
▲Enrollment UpdateAL101Trial
PROGRESS-AD Phase 2 trial of AL101/GSK4527226 has reached more than one-third of target enrollment
early Alzheimer's diseasesource ↗
●PublicationAL002DiscontinuedPresentation
Publication of preclinical and INVOKE-1 Phase 1 results for AL002 in Alzheimer's Research & Therapy
Alzheimer's diseasesource ↗
◆Topline ReadoutAL002DiscontinuedClinical Data
Topline data from INVOKE-2 Phase 2 trial of AL002 expected in Q4 2024
early Alzheimer's diseasesource ↗
●Quarterly UpdateCorporate
Cash runway guidance through 2026; Q4/FY2024 earnings call to provide 2025 guidance
◆Poster PresentationlatozinemabPresentation
Poster presentation of INFRONT-3 baseline characteristics at ISFTD 2024
frontotemporal dementia with progranulin gene mutation (FTD-GRN)source ↗
●Poster PresentationlatozinemabPresentation
Poster presentation of INFRONT-3 patient baseline characteristics at ISFTD 2024
frontotemporal dementia with progranulin gene mutation (FTD-GRN)source ↗
Past FDA Catalysts and PDUFA Decisions
How ALEC actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| 2026-10-13 | ADP065 | Pre-clinical data presentation | Pre-clinical |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
Pipeline Score
Pipeline Value
Valuation Signal
4
Drugs Scored
rNPV / MCap
Top Drug
Top 52%
Micro Cap(rank 342 of 657)
Percentile Rank
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| AL002 Monoclonal antibodyCompletedNCT03635047 | Alzheimer Disease | Phase 2 | COMPLETED | 425 | Nov 25, 2020 | ||||||
| AL003 Monoclonal antibodyCompletedNCT03822208 | Alzheimer Disease | Phase 1 | COMPLETED | 54 | May 6, 2021 | ||||||
| AL101 Monoclonal antibodyCompletedNCT04111666 | Undisclosed | Phase 1 | COMPLETED | 88 | Jun 9, 2022 | ||||||
| AL001 Monoclonal antibodyCompletedNCT03636204 | Frontotemporal Dementia | Phase 2 | COMPLETED | 97 | Dec 31, 2019 |
Clinical Trial Results
Readouts, endpoints and source filings for every ALEC program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| latozinemab BreakthroughFast TrackOrphan | frontotemporal dementia due to a GRN mutation | Phase 3 | 2025-10-21 | did not meet the clinical co-primary endpoint; statistically significant effect on the biomarker co-primary endpoint of plasma progranulin (PGRN) concentrationsRead More | Alector Announces Topline Results from Latozinemab Phase 3 Trial in Individuals with Frontotemporal Dementia Due to a GRN Mutation and Provides Business UpdateRead More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Wong-Sarad GraceOfficer (Principal Accounting Officer) | Sell | -3,625 106,015 held | $2.51 | 09/04/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in ALEC
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| TCG Crossover Management, LLC | 0.5 % (-16.7 %) | 20.10 M | 10.00 M |
ALEC Institutional Ownership Trends
ALEC Short Interest
Shares sold short, counted twice a month.
5.64%
Short % of Float
of tradable shares sold short
6.1M
Shares Sold Short
+0.7% vs prior count
5.7 High
Days to Cover
trading days of normal volume to buy every short share back
1.1M
Avg Daily Volume
the average used for days to cover
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-11-20 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How ALEC ranks across every disease it competes in
Competitive Position is a premium feature
See how ALEC ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialALEC News
ALECAlector Announces Pricing of Underwritten Offering
Alector, Inc. has announced the pricing of an underwritten offering of 36.6 million shares of common stock at $2.05 per share, raising approximately $75 million. The offering is expected to close around October 19, 2026, pending customary conditions. Proceeds will be used for general corporate purposes, including research and development.
Read more →ALEC▲ +5.2%on this news
Alector to Host Virtual Research and Development Event Highlighting Wholly Owned Alector Brain Carrier (ABC)- Enabled Pipeline
Alector, Inc. will host a virtual event on October 13, 2026, to discuss its ABC-enabled pipeline, featuring lead programs AL137, AL164, and AL062. The event aims to showcase advancements in therapies targeting neurodegenerative diseases such as Alzheimer's and Parkinson's. A live Q&A session will follow the presentation, allowing for direct engagement with the management team.
Read more →ALEC▲ +9.9%on this newsshared move
Alector Enters Global License Agreement with Genentech for Brain Penetrant GCase Enzyme Replacement Therapy for Parkinson’s Disease and Other Neurodegenerative Diseases
Alector has entered a global licensing agreement with Genentech for its investigational GCase Enzyme Replacement Therapy, AL050, aimed at treating Parkinson's Disease. The deal includes a $100 million upfront payment and potential milestone payments totaling up to $1.17 billion. AL050 utilizes Alector's proprietary technology to deliver the therapy across the blood-brain barrier, targeting GCase deficiency, a key factor in neurodegeneration.
Read more →ALECAlector to Participate in Upcoming Healthcare Conferences
Alector, Inc. announced its participation in two upcoming investor conferences: the Cantor Global Healthcare Conference on September 10, 2026, and the Morgan Stanley 24th Annual Global Healthcare Conference on September 15, 2026. The company aims to showcase its advancements in therapies for neurodegenerative diseases, leveraging genetics, immunology, and neuroscience. Webcasts of the events will be available on Alector's website.
Read more →ALECAlector Reports Second Quarter 2026 Financial Results and Provides Business Update
Alector has reported its financial results for the second quarter of 2026, highlighting advancements in its Alector Brain Carrier platform. The company is focusing on various modalities, including antibodies and siRNA, with AL137 being the lead program targeting Alzheimer's disease. Progress is also noted for other candidates like AL064 and AL164.
Read more →ALEC▼ -5.1%on this news· ran to -18% by day 1
Alector Reports First Quarter 2026 Financial Results and Provides Business Update
Alector, a biotechnology firm, reported its first quarter 2026 financial results, revealing a cash position of $206.5 million sufficient to fund operations through 2027. The company is actively advancing its Alector Brain Carrier platform, which is involved in various neurodegenerative disease programs, including Alzheimer's and Parkinson's disease therapies. However, it announced the discontinuation of the nivisnebart Phase 2 trial following a futility analysis, and collaboration revenue has decreased compared to the previous year.
Read more →ALECAlector to Discontinue Phase 2 PROGRESS-AD Trial of Nivisnebart (AL101/GSK4527226) in Early Alzheimer’s Disease Following Interim Futility Analysis
Alector has announced the discontinuation of its Phase 2 PROGRESS-AD trial for nivisnebart (AL101/GSK4527226) in early Alzheimer's disease after an independent data monitoring committee determined the trial was unlikely to meet its primary endpoint. Despite this setback, Alector is focused on advancing its pipeline of neurodegenerative disease therapies, including several promising candidates. Full results from the trial will be shared at a future medical meeting.
Read more →ALEC▲ +9.1%on this news
Alector Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
Alector, Inc. reported its fourth quarter and full year 2025 financial results, demonstrating a net loss increase and decreased collaboration revenues compared to 2024. The company highlighted its strong cash position sufficient to fund operations until at least 2027. Progress continues on its Alector Brain Carrier (ABC) platform with candidates targeting Alzheimer's and Parkinson's diseases. An interim futility analysis for the PROGRESS-AD trial is anticipated in 2026, as Alector aims to bring its promising therapies to clinical stage.
Read more →ALECAlector to Participate in the TD Cowen 46th Annual Health Care Conference
Alector, Inc. will present at the TD Cowen 46th Annual Health Care Conference on March 3, 2026. The company focuses on developing therapies for neurodegenerative diseases, including Alzheimer's and Parkinson's. A live webcast of the presentation will be available, with a replay accessible for 90 days post-event. Alector is advancing its proprietary blood-brain barrier platform to enhance therapeutic delivery.
Read more →ALECAlector Appoints Neil Berkley as Chief Financial Officer and Chief Business Officer
Alector, Inc. has appointed Neil Berkley as its Chief Financial Officer effective December 10, 2025. Berkley, who also continues as Chief Business Officer, has been with Alector since March 2024 and has contributed significantly to the company's strategic priorities. Alector is focused on developing therapies for neurodegenerative diseases and leverages a proprietary platform to enhance therapeutic delivery.
Read more →ALEC▼ -7.3%on this news
Alector to Participate in the Bank of America CNS Therapeutics Conference
Alector, Inc. will participate in the Bank of America CNS Therapeutics Conference on December 8, 2025. The event will feature a fireside chat with management, which will be available via webcast. Alector focuses on developing therapies for neurodegenerative diseases, leveraging genetics and immunology.
Read more →ALECAlector Reports Third Quarter 2025 Financial Results and Provides Business Update
Alector, Inc. announced its third-quarter financial results, highlighting a focused advancement of its innovative drug candidates aimed at neurodegenerative diseases. The company reported a cash position of $291.1 million and outlined progress on its Alector Brain Carrier platform, including lead candidates AL137 and AL050. Furthermore, the PROGRESS-AD Phase 2 trial for nivisnebart is on track for an interim analysis in the first half of 2026. However, the firm also faced challenges, including a revenue decline and the discontinuation of the latozinemab trial due to lack of clinical benefit, necessitating workforce reductions.
Read more →ALECAlector Announces Topline Results from Latozinemab Phase 3 Trial in Individuals with Frontotemporal Dementia Due to a GRN Mutation and Provides Business Update
Alector, Inc. announced that the Phase 3 INFRONT-3 trial of latozinemab in treating frontotemporal dementia due to a GRN mutation did not meet its primary clinical endpoint. While the drug showed a statistically significant impact on the biomarker endpoint of plasma progranulin concentrations, overall treatment effects on FTD-GRN were not demonstrated. Consequently, the company will discontinue the open-label extension and continuation study for the drug. Alector is also making significant operational changes, including a workforce reduction, to realign its focus on key research and clinical programs.
Read more →ALECAlector Reports Second Quarter 2025 Financial Results and Provides Business Update
Alector, Inc. has reported its financial results for the second quarter of 2025, highlighting its focus on neurodegenerative disease therapies. The company's progress includes upcoming topline data from the INFRONT-3 Phase 3 trial of latozinemab in FTD-GRN, expected by mid-Q4 2025. Despite a decline in collaboration revenue, Alector maintains a strong cash position to support ongoing research and development initiatives, including their Phase 2 trial of AL101 in Alzheimer's disease. The company continues to advance its pipeline for neurodegenerative conditions, supported by its proprietary Alector Brain Carrier technology.
Read more →ALECAlector Provides Executive Leadership Update
Alector, Inc. has appointed Neil Berkley, M.B.A., as the Interim Chief Financial Officer, succeeding Marc Grasso, M.D., who is leaving to pursue other opportunities. Berkley, who has over 20 years of experience in corporate and business development, will also retain his current role as Chief Business Officer. Alector anticipates that the company’s financial stability, with a cash runway extending into 2027, will support its ongoing clinical and research programs. The company is on track to report data from key clinical trials by the end of 2025.
Read more →ALECAlector Reports First Quarter 2025 Financial Results and Provides Business Update
Alector, Inc. reported its financial results for the first quarter of 2025, highlighting significant advancements in its clinical trials for neurodegenerative diseases. The company is on track to release topline data from the INFRONT-3 Phase 3 trial of latozinemab by Q4 2025 and has completed enrollment in the PROGRESS-AD Phase 2 trial. Alector's financial position remains strong, with $354.6 million in cash that supports its ongoing development programs into 2027. However, the company experienced a notable decline in collaboration revenue and an increase in net loss compared to the previous year.
Read more →ALECAlector Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
Alector, a biotech company, reported its Q4 and full-year 2024 financial results, highlighting a robust cash position of $413.4 million. The company is advancing its clinical programs with key milestones ahead, including topline data from the INFRONT-3 Phase 3 trial of latozinemab expected by Q4 2025 and completion of enrollment in the PROGRESS-AD Phase 2 trial by mid-2025. Alector is also progressing its innovative preclinical pipeline, aiming to deliver therapies for neurodegenerative conditions.
Read more →ALECAlector Secures Flexible Credit Facility for Up to $50 Million From Hercules Capital South San Francisco, Calif.
Alector, a clinical-stage biotechnology company, has announced a debt financing agreement with Hercules Capital for up to $50 million. This funding aims to strengthen Alector's financial position and support its preclinical pipeline, including innovative therapies for neurodegenerative diseases. The initial drawdown of $10 million has been completed, with further funding available until 2026. Alector's leadership expresses optimism for upcoming trial results that could significantly impact patient treatment options.
Read more →ALECin Alector's Quarterly Report on Form 10-Q filed on
Alector, Inc. announced the results from its INVOKE-2 Phase 2 clinical trial, which evaluated AL002 for early Alzheimer's disease. The trial results indicated that AL002 did not meet its primary endpoint of slowing disease progression, nor did it show significant effects on secondary endpoints or Alzheimer's biomarkers. As a result, Alector will cease the long-term extension study and reduce its workforce by around 17%. Nevertheless, the company remains committed to developing novel therapeutics for neurodegenerative disorders, backed by substantial financial resources.
Read more →ALECAlector Reports Third Quarter 2024 Financial Results and Provides Business Update Data from INVOKE-2, evaluating TREM2 agonist candidate AL002 in patients with early Alzheimer's disease (AD), on track for 2024 Participan
Alector, Inc. has provided a business update along with its third quarter 2024 financial results, highlighting advancements in their Alzheimer's disease and frontotemporal dementia programs. The company reported a substantial cash position of $457.2 million, enough to fund operations through 2026. Alector is set to present data from the INVOKE-2 Phase 2 trial of its TREM2 candidate AL002 in 2024, while the INFRONT-3 Phase 3 trial for frontotemporal dementia is progressing towards anticipated top-line data in late 2025 or early 2026.
Read more →About Alector, Inc.
Headquarters131 OYSTER POINT BLVD., SUITE 600, SOUTH SAN FRANCISCO, CA, 94080
Founded2013
BIOPHARMAWATCH ELITE PLUS
Trade the next ALEC catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime